NITI roadmap: India as bioeconomy powerhouse by 2035; $2.6 trn by 2047

NITI’s bioeconomy roadmap: what happened?

The bioeconomy means making things with biology: medicines, vaccines, seeds, fuels, chemicals and materials. India already supplies cheap medicines to the world. The roadmap asks India to move up, from a supplier of affordable products to a country that builds new biotechnologies and manufactures them at scale.

• The roadmap sets a mission-mode strategy to make India a leading global bioeconomy by 2035.
• Its central proposal is six National BioMissions as execution platforms.
• It stresses the convergence of AI and biology.
• It proposes carving a ₹50,000 crore BioEconomy Growth Fund out of the existing ₹1 lakh crore RDI framework.
• It builds on the BioE3 Policy, the MoS (Science and Technology) said at the launch.

What are the six National BioMissions?

What is the BioE3 Policy?

• BioE3 stands for Biotechnology for Economy, Environment and Employment.
• The Union Cabinet approved it in August 2024.
• It supports R&D and entrepreneurship in 6 thematic sectors and sets up Biomanufacturing and Bio-AI hubs and Biofoundries.
• A biofoundry works on the Design, Build, Test and Learn (DBTL) model: design with AI and computational biology, build DNA constructs, test the organisms, and learn with machine learning for the next round.

Where will the money come from?

• The roadmap proposes a ₹50,000 crore BioEconomy Growth Fund from within the ₹1 lakh crore Research, Development and Innovation (RDI) framework.
• It would fund scale-up, commercialisation, biomanufacturing infrastructure, advanced therapeutics, fermentation platforms, biomaterials, diagnostics and synthetic biology.
• In February 2026 the first national call of a ₹2,000 crore BIRAC-RDI Fund was announced under the same RDI initiative.

What do the numbers show?

A Science Ministry release of 13 Feb 2026 put the 2014 figure at about $8 billion and spoke of a $300 billion target by 2030.

How does a biofoundry turn an idea into a product?

1. Design: AI, big data and computational biology pick DNA sequences and pathways
2. Build: DNA assembly and transformation of the host organism
3. Test: screen the organisms and analyse the products
4. Learn: machine learning improves the next design
5. Scale up through biomanufacturing

Why does NITI’s bioeconomy roadmap matter?

What are the challenges in NITI’s bioeconomy roadmap?

• Official numbers differ: the 2014 base is $10 billion in this roadmap but about $8 billion in a February 2026 release.
• Targets have grown fast: $300 billion by 2030 was cited in February 2026; the roadmap now says $691 billion by 2035.
• Biotech needs long-gestation, high-risk patient capital; the Growth Fund is still only a proposal.
• Scale-up and biomanufacturing infrastructure, not research alone, will decide success.

What should be done next on NITI’s bioeconomy roadmap?

• Approve and launch the six BioMissions with clear owners and timelines.
• Set up the BioEconomy Growth Fund within the RDI framework.
• Build shared biofoundries and AI-biology platforms open to startups.
• Publish one agreed official series for bioeconomy size, so progress can be tracked.

What can Prelims ask on NITI’s bioeconomy roadmap?

• Roadmap for Building India as a Leading Bioeconomy Powerhouse by 2035: NITI Aayog, 16 July 2026.
• Bioeconomy: $195.3 billion (2025), 4.8% of GDP.
• Targets: $691 billion by 2035; $2.6 trillion by 2047.
• Six BioMissions: GeneIndia, AgriBio 2.0, BioX Foundry, One Health Grid, Marine Biotechnology, BioPharmaNext.
• BioE3 Policy: Cabinet, August 2024; DBTL biofoundry model.
• Proposed ₹50,000 crore BioEconomy Growth Fund from the ₹1 lakh crore RDI framework.

How to write about NITI’s bioeconomy roadmap in Mains

Practice question (15 marks, 250 words): Biotechnology could do for India’s next phase of growth what IT did for the last. Examine this claim in the light of NITI Aayog’s bioeconomy roadmap.

• Intro: $10 billion (2014) to $195.3 billion (2025); targets for 2035 and 2047.
• Strategy: six BioMissions, AI-biology convergence, BioE3.
• Gains: health, farm, climate, jobs.
• Hurdles: patient capital, scale-up, data mismatch.
• Way forward and conclusion.